AFM
CAPR icon

Anson Funds Management’s Capricor Therapeutics CAPR Stock Holding History

Anson Funds Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,018
Closed -$1.96M – 138
2025
Q4 		$1.96M Buy
+68,018
New +$888K 0.19% 75

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Anson Funds Management's CAPR Position: Q1 2026 in Review

Anson Funds Management sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 68,018 shares — an estimated $1.96M sold.

Anson Funds Management first reported a position in CAPR in Q4 2025 and held it in 1 quarter. The position peaked at $1.96M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Anson Funds Management reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Anson Funds Management sold 68,018 Capricor Therapeutics shares in Q1 2026, an estimated $1.96M.
  • Anson Funds Management first reported a position in Capricor Therapeutics in Q4 2025 and held it in 1 quarter.
  • Anson Funds Management's Capricor Therapeutics position peaked at $1.96M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Anson Funds Management's 13F filing for Q1 2026, filed 14 May 2026.